Recently, TKI response-related dynamic variables, such as the rate of BCR::ABL1, decline at 3 months of TKI treatment was reported as a critical prognostic discriminator of CML patients [2,9,10,11,12]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.